---
title: "Buy Rating on Xunfei Healthcare: Resilient Long-Term Growth from Expanding Medical AI Ecosystem Despite Near-Term Revenue Trim"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281064245.md"
description: "CMB International Securities analyst Jill Wu has maintained a Buy rating on Xunfei Healthcare Technology Co., Ltd., setting a price target of HK$92.55. Despite a slight revenue trim due to slower government growth, the company showed strong double-digit expansion and improved operating leverage. Wu emphasizes the firm's growth potential in China's medical AI market, supported by favorable policies and client expansion in healthcare institutions. Her analysis justifies the Buy rating, reflecting confidence in Xunfei's long-term growth prospects."
datetime: "2026-03-30T17:35:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281064245.md)
  - [en](https://longbridge.com/en/news/281064245.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281064245.md)
---

# Buy Rating on Xunfei Healthcare: Resilient Long-Term Growth from Expanding Medical AI Ecosystem Despite Near-Term Revenue Trim

CMB International Securities analyst Jill Wu maintained a Buy rating on Xunfei Healthcare Technology Co., Ltd. today and set a price target of HK$92.55.

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Jill Wu has given his Buy rating due to a combination of factors related to Xunfei Healthcare’s growth profile and strategic positioning in China’s medical AI market. Despite revenue landing slightly below her prior forecast because of slower government-end growth in the second half, she notes that the company still delivered strong double-digit top-line expansion, a sharp narrowing of net loss, and meaningful operating leverage improvements.

She also highlights rapid client expansion across primary healthcare institutions and hospitals, supported by favorable policies promoting AI-assisted diagnosis, as well as the growing contribution of patient-facing services that provide more recurring, consumer-based revenue. In her view, the firm’s ability to turn its government and hospital relationships into scalable C-end applications, combined with solid execution on its GBC (government–business–consumer) model, underpins resilient long-term growth, justifying a Buy rating even after trimming revenue forecasts and valuation multiples.

According to TipRanks, Wu is a 5-star analyst with an average return of 30.8% and a 51.92% success rate. Wu covers the Healthcare sector, focusing on stocks such as CSPC Pharmaceutical Group, WuXi XDC Cayman, Inc., and Pfizer.

### Related Stocks

- [002230.CN](https://longbridge.com/en/quote/002230.CN.md)
- [02506.HK](https://longbridge.com/en/quote/02506.HK.md)
- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)
- [159898.CN](https://longbridge.com/en/quote/159898.CN.md)
- [159883.CN](https://longbridge.com/en/quote/159883.CN.md)

## Related News & Research

- [Broncus shareholders back all AGM resolutions, update articles of association](https://longbridge.com/en/news/286439966.md)
- [Healthcare AI firm Commure valued at $7 billion, raises $70 million](https://longbridge.com/en/news/286936246.md)
- [Citadel CEO Ken Griffin was a prominent AI skeptic. Now he says, 'AI is real.'](https://longbridge.com/en/news/286683665.md)
- [AI face is taking over — and driving plastic surgeons crazy](https://longbridge.com/en/news/286641783.md)
- [08:17 ETHartford HealthCare and Vitea Partner to Advance Responsible AI Innovation Across Healthcare](https://longbridge.com/en/news/286911045.md)